Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Interim report, May-October 2020/21
2020-11-26 15:01
Gustaf Salford appointed Elekta CEO by Board of Directors
2020-11-26 14:59
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
2020-11-26 14:04
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations
2020-11-26 10:34
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
2020-11-26 10:32
Frost & Sullivan Examines 8 Strategic Imperatives for Growth in a Post-COVID World
2020-11-26 01:23
Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone
2020-11-26 01:17
RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA
2020-11-25 16:06
Indonesia's Government to Help Improve the Welfare of Non-Civil Servant Educators and Educational Personnel Through Wage Subsidies
2020-11-25 13:11
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2020-11-25 08:27
MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients
2020-11-25 08:00
Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Awardees of the Seoul Innovation QuickFire Challenge on Healthcare for the New Normal in Collaboration with the Seoul Metropolitan Government and Korea Health Industry Development Institute
2020-11-25 07:00
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
2020-11-25 07:00
Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2020-11-25 06:00
China Biologic Reports Financial Results for the Third Quarter of 2020
2020-11-25 05:30
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021
2020-11-25 05:16
The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets
2020-11-25 04:38
PwC Actuarial Services Hails Aon's PathWise® Platform for IFRS 17 Reporting
2020-11-24 23:00
NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound Symposium
2020-11-24 22:26
Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose
2020-11-24 22:14
1
699
700
701
702
703
1607